Sacituzumab Govitecan for Advanced Esophageal Squamous Cell Carcinoma

Phase 2 Recruiting 35 enrolled National Taiwan University Hospital Gilead Sciences · collab

NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical trial is to investigate the efficacy and safety of sacituzumab govitecan in patients with advanced esophageal squamous cell carcinoma.

Timeline

Start: 2024-08-01
Primary completion: 2026-11
Completion: 2027-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sacituzumab Govitecan	Monoclonal antibody	10 mg/kg	Intravenous

Sacituzumab Govitecan for Advanced Esophageal Squamous Cell Carcinoma

Summary

Timeline

Drugs

Indications